JP2015527387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527387A5 JP2015527387A5 JP2015530495A JP2015530495A JP2015527387A5 JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5 JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 255
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 79
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- -1 trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000001589 carboacyl group Chemical group 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216017.2 | 2012-09-07 | ||
| GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
| PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Division JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527387A JP2015527387A (ja) | 2015-09-17 |
| JP2015527387A5 true JP2015527387A5 (enExample) | 2017-09-07 |
| JP6216791B2 JP6216791B2 (ja) | 2017-10-18 |
Family
ID=47137117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530495A Active JP6216791B2 (ja) | 2012-09-07 | 2013-09-09 | 阻害剤化合物 |
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9409907B2 (enExample) |
| EP (2) | EP3293183B1 (enExample) |
| JP (2) | JP6216791B2 (enExample) |
| CN (1) | CN104837829B (enExample) |
| AU (2) | AU2013311434B2 (enExample) |
| BR (1) | BR112015004489B1 (enExample) |
| CA (1) | CA2884006C (enExample) |
| CY (1) | CY1119714T1 (enExample) |
| DK (2) | DK2892889T3 (enExample) |
| ES (2) | ES2742442T3 (enExample) |
| GB (1) | GB201216017D0 (enExample) |
| HR (1) | HRP20171835T1 (enExample) |
| HU (1) | HUE036259T2 (enExample) |
| LT (1) | LT2892889T (enExample) |
| NO (1) | NO2892889T3 (enExample) |
| PL (1) | PL2892889T3 (enExample) |
| PT (1) | PT2892889T (enExample) |
| RS (1) | RS56750B1 (enExample) |
| RU (1) | RU2673079C2 (enExample) |
| SI (1) | SI2892889T1 (enExample) |
| SM (1) | SMT201700596T1 (enExample) |
| WO (1) | WO2014037750A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| EP3231804B1 (en) | 2008-03-21 | 2021-03-03 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| ES3069593T3 (en) * | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| US10124004B2 (en) * | 2015-05-29 | 2018-11-13 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
| US10494378B2 (en) | 2015-07-21 | 2019-12-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| CN109843858B (zh) | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| TWI755452B (zh) | 2016-11-28 | 2022-02-21 | 日商帝人製藥股份有限公司 | 吡啶并〔３﹐４-ｄ〕嘧啶衍生物或其溶劑合物之結晶 |
| HUE053220T2 (hu) * | 2016-11-28 | 2021-06-28 | Teijin Pharma Ltd | ((Piridin-2-il)-amino)pirido[3,4-d]pirimidin és ((piridazin-3-il)-amino)pirido[3,4-d]pirimidin származékok mint CDK4/6 inhibitorok pl. reumatoid artritisz, érelmeszesedés, tüdõfibrózis, agyi infartus vagy rák kezelésére |
| GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| WO2018234778A1 (en) * | 2017-06-20 | 2018-12-27 | The Institute Of Cancer Research: Royal Cancer Hospital | METHODS AND MEDICAL USES |
| EP3701304B1 (en) | 2017-10-26 | 2022-05-04 | CommScope Connectivity Belgium BVBA | Telecommunications system |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| GB201809458D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| BR112022008375A2 (pt) | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| US11267788B2 (en) * | 2020-07-16 | 2022-03-08 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating AhR imbalance |
| CN115942937B (zh) * | 2020-08-17 | 2025-07-25 | 浙江扬厉医药技术有限公司 | 嘧啶并环类化合物 |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| CN115583946B (zh) * | 2021-07-06 | 2026-01-16 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其作为cdk抑制剂的用途 |
| AR128015A1 (es) * | 2021-12-16 | 2024-03-20 | Transthera Sciences Nanjing Inc | Inhibidor de cdk9 y uso del mismo |
| CN121548580A (zh) * | 2023-05-15 | 2026-02-17 | 亚历克西亚治疗公司 | Cdk抑制剂化合物 |
| WO2025038785A1 (en) * | 2023-08-16 | 2025-02-20 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications |
| CN117800875B (zh) * | 2023-12-21 | 2024-10-22 | 泰州精英化成医药科技有限公司 | 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法 |
| TW202545531A (zh) * | 2024-01-17 | 2025-12-01 | 美商依安彼克醫療有限公司 | 氮—喹唑啉化合物之使用方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| FI971953A7 (fi) | 1994-11-14 | 1997-05-12 | Warner Lambert Co | Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| WO2001055147A1 (en) | 2000-01-25 | 2001-08-02 | Warner-Lambert Company | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| AU2002324450A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| EP1463505A2 (en) | 2001-12-13 | 2004-10-06 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| KR100714519B1 (ko) | 2002-03-07 | 2007-05-07 | 에프. 호프만-라 로슈 아게 | 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제 |
| RU2324695C2 (ru) * | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38 |
| CA2765093A1 (en) | 2002-11-12 | 2004-05-27 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| ATE541844T1 (de) * | 2005-12-21 | 2012-02-15 | Abbott Lab | Antivirale verbindungen |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2673003A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| WO2009084695A1 (ja) * | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
| US9333205B2 (en) * | 2010-07-30 | 2016-05-10 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| US8975267B2 (en) * | 2011-01-26 | 2015-03-10 | Nerviano Medical Sciences S.R.L. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
| US9517229B2 (en) | 2011-07-29 | 2016-12-13 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| EP2766352B1 (en) | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| EP2961409A1 (en) | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| MX2016007282A (es) | 2013-12-06 | 2016-09-07 | Hoffmann La Roche | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| SG10201807838SA (en) | 2014-03-11 | 2018-10-30 | Council Queensland Inst Medical Res | Determining cancer aggressiveness, prognosis and responsiveness to treatment |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| US10611765B2 (en) | 2014-11-06 | 2020-04-07 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors |
| GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| WO2018234778A1 (en) | 2017-06-20 | 2018-12-27 | The Institute Of Cancer Research: Royal Cancer Hospital | METHODS AND MEDICAL USES |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh not_active Expired - Fee Related
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
- 2013-09-09 SM SM20170596T patent/SMT201700596T1/it unknown
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en not_active Ceased
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en not_active Ceased
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
- 2013-09-09 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt not_active IP Right Cessation
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
-
2016
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
- 2016-04-06 US US15/091,887 patent/US9890157B2/en not_active Expired - Fee Related
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja not_active Expired - Fee Related
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en not_active Ceased
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en not_active Expired - Fee Related
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529217A5 (enExample) | ||
| JP2016501191A5 (enExample) | ||
| CN114222743A (zh) | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 | |
| HRP20180331T1 (hr) | Spojevi n-pirolidinil, n'pirazolil- urea, tiourea, gvanidin i cijanogvanidin kao inhibitori trka kinaze | |
| JP2016537382A5 (enExample) | ||
| JP2015537001A5 (enExample) | ||
| JP2022522777A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2019514874A5 (enExample) | ||
| ME02879B (me) | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola | |
| JP2014500296A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2018516904A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2017521375A5 (enExample) | ||
| JP2013532130A5 (enExample) | ||
| JP2015535847A5 (enExample) |